<DOC>
	<DOC>NCT02045433</DOC>
	<brief_summary>The purpose of this study is to determine whether SABR boost therapy is effective in women with locally advanced cervical cancer without increased risk of acute gastrointestinal (GI) or genitourinary (GU) toxicity.</brief_summary>
	<brief_title>Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>Patients enrolled in this study will receive 45 Gray (Gy) in 25 fractions of intensity modulated external beam radiation therapy + weekly cisplatinum . Following the completion of Intensity Modulated Radiation Therapy (IMRT), patients will receive 28 Gy in 4 fractions using stereotactic body radiation therapy techniques.</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<criteria>1 Locally Advanced stage Cervical Cancer 2. Zubrod performance status 02 3. Negative urine or serum pregnancy test for women of childbearing potential 4. Agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study treatment 5. Not a candidate for intracavitary brachytherapy 1. Pregnancy 2. Concurrent untreated cancer excluding nonMelanoma skin cancer 3. Previous pelvic radiation 4. Active Inflammatory Bowel disease, Collagen vascular disease systemic lupus erythematosus (SLE), scleroderma 5. Age &lt;18 6. Unable to consent for study 7. Severely immunocompromised patients ( such as Transplant , on immunosuppressive drugs)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>